Accessing our website tells us you are happy to receive all our cookies. However you can change your cookie settings at any time.

Privacy & Cookies

You are leaving our website

You have clicked on a link that will take you to a third-party website that Alliance Pharmaceuticals plc group (“Alliance”) is not responsible for.

Please read the following disclaimer and click “I agree” to proceed to the third-party website.

By clicking to continue you agree that:You are leaving Alliance`s website.

Alliance:

  • Is not responsible for the content or accuracy of the third-party website nor endorse or guarantee any services or information they may offer.
  • Does not represent either the third-party website or you (the visitor) if you enter into an agreement or transaction.
  • Privacy and security policies do not apply to third-party websites.
or Decline

Our Financial Highlights for H1 2020

The first half of 2020 saw a robust performance, against the backdrop of COVID-19.

Continued strong performance from our Consumer Healthcare brands, led by KELO-COTETM

Operating leverage maintained and underlying pre-tax profits increased, despite a small reduction in revenue

New line extension for NizoralTM launched in China in July 2020; good progress continues to be made with bringing the Nizoral business fully under our control

Cash generation remained robust, with a further fall in leverage

To view in detail click here to download our 2020 Interim Report

currently counter number sum counter number

See-through revenue*

currently counter number sum counter number

Underlying Profit Before Tax

currently counter number sum counter number

Underlying Basic Earnings per Share

currently counter number sum counter number

Free Cash Flow*

currently counter number sum counter number

Leverage

currently counter number sum counter number

Interim Dividend per Share

Please view our five year financial summary below

Five Year Summary
Year ended 31 December 2015 £mYear ended 31 December 2016 £mYear ended 31 December 2017 £mYear ended 31 December 2018 £mYear ended 31 December 2019 £m
Revenue48.397.5101.6118.2135.6
Operating profit before non-underlying items10.625.625.828.937.4
Non-underlying operating items(6.3)-4.4(5.3)(1.8)
Operating profit17.025.630.223.735.6
Profit before tax before non-underlying items11.022.223.928.132.9
Profit before tax after non-underlying items15.222.228.322.831.1
Intangible assets259.9264.8278.6335.2328.7
Tangible assets1.01.85.77.611.6
Current assets27.849.349.158.765.0
Current liabilities31.850.361.491.724.2
Equity162.4179.3203.1252.2274.2
Average shares in issue (millions)272.7469.4473.8497.2520.7
Shares in issue at period end (millions)468.2472.6475.0518.2529.4
Earnings per share – basic (p)4.653.856.083.694.80
Earnings per share – adjusted underlying basic (p)3.693.694.054.545.09

* Non-IFRS alternative performance measures (see note 17). See-through revenue includes sales from Nizoral as if they had been invoiced by Alliance. For statutory accounting purposes the product margin on Nizoral sales is included within Revenue, in line with IFRS 15